Developing a first-in-class approach for
liver fibrosis
Hepacure is developing a first-in-class, dual-acting peptide therapy designed to address two biological drivers of liver fibrosis in MASH.
About HepaCure Pharma
A novel peptide therapy for MASH
Understanding MASH
MASH — metabolic dysfunction-associated steatohepatitis — is a serious form of fatty liver disease marked by liver inflammation and injury.
Understanding MASH
MASH — metabolic dysfunction-associated steatohepatitis — is a serious form of fatty liver disease marked by liver inflammation and injury.
The unmet need
Over time, ongoing inflammation can drive liver fibrosis: scar tissue that can lead to cirrhosis, liver failure and liver cancer. Despite recent advances, MASH remains difficult to treat.
The unmet need
Over time, ongoing inflammation can drive liver fibrosis: scar tissue that can lead to cirrhosis, liver failure and liver cancer. Despite recent advances, MASH remains difficult to treat.
A new treatment approach
Hepacure’s Luji programme is a unique dual-acting peptide therapy designed to address fibrosis through complementary immune and cellular mechanisms.
A new treatment approach
Hepacure’s Luji programme is a unique dual-acting peptide therapy designed to address fibrosis through complementary immune and cellular mechanisms.
The MASH challenge
0%
0%
Estimated proportion of adults affected by MASH globally
0%
0%
Estimated proportion of adults affected by MASH globally
0M
0M
People projected to be affected by MASH worldwide by 2030
0M
0M
People projected to be affected by MASH worldwide by 2030
0%
0%
Estimated proportion of people with fatty liver disease who may progress to MASH
0%
0%
Estimated proportion of people with fatty liver disease who may progress to MASH
0%
0%
Estimated risk of developing advanced fibrosis
0%
0%
Estimated risk of developing advanced fibrosis
Our solution
Lead programme Luji:
a dual-acting approach
Luji is Hepacure’s investigational lead programme for MASH-related liver fibrosis. It is designed to reduce the signals that drive scar formation while reactivating the body’s natural anti-fibrotic immune response.
MASH-related fibrosis
Luji’s initial focus is liver fibrosis associated with MASH
MASH-related fibrosis
Luji’s initial focus is liver fibrosis associated with MASH
Reducing scar-forming signals
Blocks two key proteins in the fibrosis pathway
Reducing scar-forming signals
Blocks two key proteins in the fibrosis pathway
Reducing scar-forming signals
Blocks two key proteins in the fibrosis pathway
First-in-class peptide
A novel peptide approach to progressive liver scarring
First-in-class peptide
A novel peptide approach to progressive liver scarring
First-in-class peptide
A novel peptide approach to progressive liver scarring
Reactivating anti-fibrotic defences
Reactivates immune cells, including NK cells that help keep fibrotic processes in check
Reactivating anti-fibrotic defences
Reactivates immune cells, including NK cells that help keep fibrotic processes in check
Reactivating anti-fibrotic defences
Reactivates immune cells, including NK cells that help keep fibrotic processes in check
Once-weekly injection
Developed for once-weekly subcutaneous administration
Once-weekly injection
Developed for once-weekly subcutaneous administration
Preclinical evidence
Advancing from successful preclinical animal studies
Preclinical evidence
Advancing from successful preclinical animal studies
Preclinical evidence
Advancing from successful preclinical animal studies
Our people
Meet The Team
Meet The Team
FAQs
Frequently Asked Questions
What is MASH?
MASH stands for metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease marked by liver inflammation and injury.
What is liver fibrosis?
What is Hepacure developing?
What is the Luji programme?
What stage is the Luji programme in?
What is MASH?
MASH stands for metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease marked by liver inflammation and injury.
What is liver fibrosis?
What is Hepacure developing?
What is the Luji programme?
What stage is the Luji programme in?
Advancing a new treatment approach to MASH
For enquiries regarding Hepacure Pharma, the Luji programme or potential collaboration opportunities, please get in touch.
© 2026 Hepacure Pharma. All rights reserved.
Advancing a new treatment approach to MASH
For enquiries regarding Hepacure Pharma, the Luji programme or potential collaboration opportunities, please get in touch.
© 2026 Hepacure Pharma. All rights reserved.
Advancing a new treatment approach to MASH
For enquiries regarding Hepacure Pharma, the Luji programme or potential collaboration opportunities, please get in touch.
© 2026. All rights reserved.